Cathie's Ark Logo
Repare Therapeutics Inc Logo

ARKG Holdings of Repare Therapeutics (RPTX) - Updated Daily

TherapeuticsGene TherapyCRSPR Gene Editing
Date
Direction
Shares
Fund Weight
Fund
August 30, 2021
BUY816.0000.0003%ARKG
August 27, 2021
BUY7.501k0.003%ARKG
August 26, 2021
BUY2.468k0.001%ARKG
August 24, 2021
BUY229.0000.0001%ARKG
August 20, 2021
BUY2.935k0.0012%ARKG

Key Statistics

⚖️Weighting🧢Market Cap
1.86%$406.63m
🏋🏿‍♂️Weight Rank In ARKG🌏Country
22🇨🇦Canada
🏋️‍♀️Weight Rank Across All Funds💳ARK Estimated Cost Average
52
🎫ARK Ownership Percent
6.12%
Description
repare therapeutics is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells. its approach integrates insights from several fields of cell biology including dna repair and synthetic lethality. repare’s platform combines a proprietary, high throughput, crispr‐enabled gene editing target discovery method with high‐resolution protein crystallography, computational biology and clinical informatics. the company is backed by leading global healthcare investors including founding investor versant ventures and mpm capital. for additional information, please visit www.reparerx.com.
Website
reparerx.com

Other ETFs That Hold RPTX

Ticker
NameWeight
ARKGARK Genomic Revolution ETF1.42%
IBBiShares Biotechnology ETF0.04%

Research Notes and Commentary for RPTX

No Research Notes Found for RPTX